Cambridge biopharma specialist Microbiotica, which recently clinched $48 million Series C cash, has swiftly underlined its potential by hitting the target with its latest trial results.

The company, which is developing a pipeline of precision microbiome medicines, presented clinical data with encouraging efficacy from its Phase 1b MELODY-1 trial of MB097 to combat advanced melanoma, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.

The trial met all its primary and secondary endpoints. MB097 was found to be safe and well tolerated in combination with KEYTRUDA® (pembrolizumab), with no serious adverse effects related to MB097.

The nine-strain bacterial consortium demonstrated rapid, robust and persistent engraftment, particularly in patients receiving vancomycin preconditioning.

Professor Paolo Ascierto, Director of the Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics at University of Naples Federico II, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy and a National Co-ordinating Investigator for the MELODY-1 study, said: “The advanced melanoma patients enrolled in MELODY-1 had recently received anti-PD-1 therapy but continued to experience disease progression.

“Many had received multiple prior lines of treatment, including combination immune checkpoint inhibitor regimens, without achieving a meaningful clinical benefit. This represents a particularly challenging patient population with limited therapeutic options.

“It is therefore encouraging to observe clinically meaningful responses, including deep tumour regressions, suggesting that modulation of the gut microbiome with MB097 may help restore sensitivity to pembrolizumab in patients previously refractory to anti-PD-1 therapy.

“These findings provide an important early clinical proof-of-concept for microbiome-based strategies aimed at enhancing the effectiveness of cancer immunotherapy and warrant further investigation in larger clinical studies.”

MB097 is an oral, once-daily live therapeutic comprising a consortium of nine bacterial strains identified through the analysis of four clinical studies in the US and Europe using Microbiotica’s genomics-driven microbiome platform.

It is being evaluated in an international Phase 1b clinical study (MELODY-1) which is assessing MB097’s safety and tolerability when administered once daily in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with advanced melanoma.

The trial recruited 41 patients with advanced melanoma whose cancer had failed to respond at any time to treatment with anti-PD-1 antibody therapy (primary refractory) at clinical centres in the UK, France, Italy and Spain.

Robert Tansley, Chief Medical Officer, Microbiotica, said: “Growing evidence highlights the role of the gut microbiome in patients’ responses to immune checkpoint inhibitors, particularly anti-PD-1 therapies. The data presented at ESMO from our Phase 1b MELODY-1 study demonstrates that MB097 was safe and well tolerated in combination with KEYTRUDA, with robust, persistent engraftment of the bacterial consortium and encouraging clinical responses in this challenging patient population.

“These findings support further evaluation of MB097 and we look forward to generating additional data from the extension phase as we continue to investigate its potential for patients with melanoma who do not respond to anti-PD-1 therapy.”